Media stories about CASI Pharmaceuticals (NASDAQ:CASI) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CASI Pharmaceuticals earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.5232559179795 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Shares of CASI Pharmaceuticals (NASDAQ CASI) traded up $0.02 during midday trading on Wednesday, reaching $3.24. 25,217 shares of the company traded hands, compared to its average volume of 225,563. The stock has a market cap of $223.69, a price-to-earnings ratio of -21.60 and a beta of 0.87. CASI Pharmaceuticals has a 12 month low of $0.91 and a 12 month high of $4.84.
Several equities research analysts recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $4.50 price target on shares of CASI Pharmaceuticals in a report on Monday, January 29th. BidaskClub lowered shares of CASI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 14th. ValuEngine lowered shares of CASI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday. Finally, Maxim Group set a $4.00 price target on shares of CASI Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, November 14th.
CASI Pharmaceuticals Company Profile
CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.